Measured by its ability to neutralize M-CSF R/CD115-mediated inhibition of proliferation in the M‑NFS‑60 mouse myelogenous leukemia lymphoblast cell line. The Neutralization Dose (ND50) is typically 4-16 ng/mL in the presence of 30 ng/mL Recombinant Human M-CSF R/CD115 Fc Chimera and 1 ng/mL Recombinant Human M-CSF.
Please Note: Optimal dilutions should be determined by each laboratory for each application.
are available in the Technical Information section on our website.
Detection of Human M-CSF R/CD115 by Western Blot.
Western blot shows lysates of THP‑1 human acute monocytic leukemia cell line. PVDF membrane was probed with 2 µg/mL of Mouse Anti-Human M-CSF R/CD115 Monoclonal Antibody (Catalog # MAB3291) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for M-CSF R/CD115 at approximately 130 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
M-CSF R/CD115 Inhibition of M-CSF-dependent Cell Proliferation and Neutralization by Human M-CSF R/CD115 Antibody.
Recombinant Human M-CSF R/CD115 Fc Chimera (Catalog # 329-MR) inhibits Recombinant Human M-CSF (Catalog # 216-MC) induced proliferation in the M‑NFS‑60 mouse myelogenous leukemia lymphoblast cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human M-CSF R/CD115 (1 ng/mL) activity elicited by Recombinant Human M-CSF R/CD115 Fc Chimera (30 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human M-CSF R/CD115 Monoclonal Antibody (Catalog # MAB3291). The ND50 is typically 4-16 ng/mL.
Preparation and Storage
Reconstitute at 0.5 mg/mL in sterile PBS.
Reconstitution Buffer Available
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: M-CSF R/CD115
M-CSF receptor, the product of the c-fms proto-oncogene, is a member of the type III subfamily of receptor tyrosine kinases that also includes receptors for SCF and PDGF. These receptors each contain five immunoglobulin-like domains in their extracellular domain (ECD) and a split kinase domain in their intracellular region (1-4). M-CSF receptor is expressed primarily on cells of the monocyte/macrophage lineage, dendritic cells, stem cells and in the developing placenta (1). Human M-CSF receptor cDNA encodes a 972 amino acid (aa) type I membrane protein with a 19 aa signal peptide, a 493 aa extracellular region containing the ligand-binding domain, a 25 aa transmembrane domain, and a 435 aa cytoplasmic domain. The human M-CSF R ECD shares 60%, 64%, 72%, 75%, 75%, and 76% aa identity with mouse, rat, bovine, canine, feline, and equine M-CSF R, respectively. Activators of protein kinase C induce TACE/ADAM17 cleavage of the M-CSF receptor, releasing the functional ligand-binding extracellular domain (5). M-CSF binding induces receptor homodimerization, resulting in transphosphorylation of specific cytoplasmic tyrosine residues and signal transduction (6). The intracellular domain of activated M-CSF R binds more than 150 proteins that affect cell proliferation, survival, differentiation and cytoskeletal reorganization. Among these, PI3Kinase, P42/44 ERK, and c-Cbl are key transducers of M-CSF R signals (3, 4). M-CSF R engagement is continuously required for macrophage survival and regulates lineage decisions and maturation of monocytes, macrophages, osteoclasts, and DC (3, 4). M-CSF R and integrin alpha v beta 3 share signaling pathways during osteoclastogenesis and deletion of either causes osteopetrosis (7, 8). In the brain, microglia expressing increased M-CSF R are concentrated with Alzheimers a beta peptide, but their role in pathogenesis is unclear (9, 10).
deParseval, N. et al. (1993) Nucleic Acids Res. 21:750.
Rothwell, V.M. and L.R. Rohrschneider (1987) Oncogene Res. 1:311.
Chitu, V. and E.R. Stanley (2006) Curr. Opin. Immunol. 18:39.
Ross, F.P. and S.L. Teitelbaum (2005) Immunol. Rev. 208:88.
Rovida, E. et al. (2001) J. Immunol. 166:1583.
Yeung, Y. et al. (1998) J. Biol. Chem. 273:17128.
Dai, X. et al. (2002) Blood 99:111.
Faccio, R. et al. (2003) J. Clin. Invest. 111:749.
Li, M. et al. (2004) J. Neurochem. 91:623.
Mitrasinovic, O.M. et al. (2005) J. Neurosci. 25:4442.
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.